Attana AB: Maximising Drug Discovery Research

Teodor Aastrup from Attana AB, a sponsor company at the marcus evans Discovery Summit 2011, on biologics for maximising drug discovery research productivity

CANNES, France--(BUSINESS WIRE)--

Discovery Summit 2011
CANNES, France, 21 - 23 March

Interview with: Teodor Aastrup, Chief Executive Officer, Attana AB

Drug discovery scientists should focus on the biological relevance of their candidate molecules as soon as possible in their research, to ensure a high probability of success in later stages”, says Teodor Aastrup, Chief Executive Officer and Founder of Attana AB. To maximise productivity, there is a need to understand reactions and interactions in the human body before research has advanced too much. From a sponsor company at the upcoming marcus evans Discovery Summit 2011 in Cannes, France, 21 - 23 March, Aastrup discusses the role biologics can play in speeding up drug discovery and subsequent stages.

How can drug discovery become more efficient?

Teodor Aastrup: “It is crystal clear to me that drug discovery scientists should focus on the biological relevance of molecules early on in their research, to ensure a high probability of success in later stages. If they start working with cells and functional assays that better mimic what cells do in the body during clinical trials, they will obtain much better information to work with. This will speed up the process, as all their efforts will be focused on taking potentially successful candidates through to the clinical trial phase.

Simply knowing a molecule does not work perfectly is not enough; characterising molecules in a more natural environment gives us the ability to understand why they are not working. If we do this earlier, we can increase our success rate.”

What are your thoughts on the regulatory landscape?

Teodor Aastrup: “Regulations have increased, with more requirements in every step, from being able to begin clinical trials until the drug is approved. The tools that scientists use are not all up to date with this. While new tools do exist, they also have to be validated.

Nevertheless, there is a need to reconsider how efficient certain processes are, which could be time consuming. Internal resources have to be challenged; everything must be questioned. People who have been working in a particular way for 20 years might be reluctant to change the way they work, but technologies have improved and there could be better ways to do certain things. The Chief Scientific Officer has to be visionary, get everyone on board and working on all possibilities that exist. Valuable knowledge from standardised processes needs to be transferred into the newer technologies.”

What are some of the scientific areas or technologies worth following?

Teodor Aastrup: “The trend of biologics will continue, as molecules that are designed to fit inside the body will be better drug candidates. Chemical entities also have a bright future when combined with biologics - we will be able to add good properties, place the synthetic drug on an antibody and achieve a double impact. Improving technologies will give us a more mechanical understanding of molecular interaction, and a better chance of improving drug candidates.”

Summit Website: www.discovery-summit.com/TABW

marcus evans group life sciences / pharma sector portal

About Attana AB

Founded in 2002, based in Stockholm, Sweden, Attana AB develops biosensors for the pharmaceutical, diagnostic and academic society worldwide. With a strong focus on characterizing molecular interactions exactly as they occur in the human body, Attana is committed to increasing success during clinical trials by providing the life science community with biologically relevant information. Attana’s biosensors can be used to determine specificity, kinetics and affinity, amongst other binding characteristics of biomolecules and macrostructures of varying species such as cells, antibodies, proteins, viruses and bacteria.

www.attana.com



CONTACT:

marcus evans
Press Manager
Summits Division
Sarin Kouyoumdjian-Gurunlian
Tel: + 357 22 849 313
Email: [email protected]

KEYWORDS:   Europe  France

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.